Healios K.K. (TYO:4593)

Japan · Delayed Price · Currency is JPY

270.00

+2.00 (0.75%)

Oct 26, 2026, 3:30 PM JST

Market Cap	36.60B -35.7%
Revenue (ttm)	59.00M -47.3%
Net Income	207.00M
EPS	-7.51
Shares Out	135.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,033,500
Open	265.00
Previous Close	268.00
Day's Range	258.00 - 270.00
52-Week Range	208.00 - 514.00
Beta	1.35
Analysts	Buy
Price Target	794.83 (+194.38%)
Earnings Date	Nov 12, 2026

About Healios K.K.

Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ischemic stroke; and HLCM051, which is in phase 2 clinical trial for the treatment of trauma, as well as HLCR011, which is in phase 1/2 clinical trial for t... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2011

Employees 75

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4593

Full Company Profile

Financial Performance

In 2025, Healios K.K.'s revenue was 104.00 million, a decrease of -81.43% compared to the previous year's 560.00 million. Losses were -2.22 billion, -47.65% less than in 2024.

Financial Statements

Analyst Summary

According to 6 analysts, the average rating for 4593 stock is "Buy." The 12-month stock price target is ¥795, which is an increase of 194.38% from the latest price.

Price Target

¥795

(194.38% upside)

Analyst Consensus: Buy

Stock Forecasts